Figure 4.
Decision-curve analysis using the LAWS score for predicting 30-day mortality of ICH in 106 patients from both the derivation and external validation cohorts. Black line (treat none) shows the net benefit when we assume no allo-HSCT patient dies within 30 days of ICH diagnosis; gray line (treat all) shows the net benefit when we assume all allo-HSCT patients die within 30 days of ICH diagnosis; and dashed line (LAWS score) shows the net benefit when we manage allo-HSCT patients with ICH according to the predicted risk of 30-day mortality estimated by LAWS score. The preferred management strategy is the one with the highest net benefit at each given threshold probability.